Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jul 1;346(8966):26-8.
doi: 10.1016/s0140-6736(95)92654-2.

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

M W Saville  1 , J Lietzau, J M Pluda, I Feuerstein, J Odom, W H Wilson, R W Humphrey, E Feigal, S M Steinberg, S Broder, et al.
Affiliations
Clinical Trial

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

M W Saville et al. Lancet. .

Abstract

We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% CI 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies, including a randomised trial, are warranted.

PubMed Disclaimer

Publication types